remdesivir: Jubilant Pharmova surges as company develops Remdesivir oral form

MUMBAI: Jubilant Pharma subsidiary Jubilant Pharmova's shares soared as much as 10 per cent on Monday after the company announced that it haD developed an oral version of critical Covid-19 treatment drug Remdesivir.
“Jubilant has sought authorisation for additional studies for this novel oral formulation from the Drug Controller General of India. Jubilant is hoping to provide an affordable, more convenient, easy-to-administer and potentially effective treatment option for Covid-19 patients,” the company said in an exchange filing.
Remdesivir has been in high demand in the country in the wake of surging Covid-19 infections over the past one month. Hospitals and pharmacists in major cities have reported acute shortage of the drug due to supply constraints and alleged hoarding.

Related Keywords

Mumbai , Maharashtra , India , , National Stock Exchange , Jubilant Pharma , Jubilant Pharmova , Drug Controller General , Gilead Science , National Stock , Remdesivir , Dgci , Covid News , Covid Drug , Jubilant Pharmova Ltd , Covid 19 Lockdown , Covid Treatment , Covid Vaccine , மும்பை , மகாராஷ்டிரா , இந்தியா , தேசிய ஸ்டாக் பரிமாற்றம் , மகிழ்ச்சி பார்மா , மருந்து கட்டுப்படுத்தி ஜநரல் , கிலியட் அறிவியல் , தேசிய ஸ்டாக் ,